Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377:2433–44.
Vyas A, Raval AD, Kamat S, LaPlante K, Tang Y, Chemaly RF. Real-world outcomes associated with letermovir use for cytomegalovirus primary prophylaxis in allogeneic hematopoietic cell transplant recipients: a systematic review and meta-analysis of observational studies. Open Forum Infect Dis. 2023;10:ofac687.
Russo D, Schmitt M, Pilorge S, Stelljes M, Kawakita T, Teal VL, et al. Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol. 2024;11:e127–e35.
Sadowska-Klasa A, Ozkok S, Xie H, Leisenring W, Zamora D, Seo S, et al. Late cytomegalovirus disease after hematopoietic cell transplantation: significance of novel transplantation techniques. Blood Adv. 2024;8:3639–51.
Yong MK. CMV antiviral stewardship in transplantation – the next frontier. Curr Opin Infect Dis. 2023;36:495–6.
Sassine J, Siegrist EA, Shafat TF, Chemaly RF. Advances and prospect in herpesviruses infections after haematopoietic cell transplantation: closer to the finish line? Clin. Microbiol. Infect. 2024;36:49–56.
Razonable RR. Pathogen-specific cell-mediated immunity to guide the management of cytomegalovirus in solid organ transplantation: state of the art clinical review. Expert. Rev. Clin. Immunol. 2024;20:1–14.
Kumar D, Chernenko S, Moussa G, Cobos I, Manuel O, Preiksaitis J, et al. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transpl. 2009;9:1214–22.
Banas B, Boger CA, Luckhoff G, Kruger B, Barabas S, Batzilla J, et al. Validation of T-Track(R) CMV to assess the functionality of cytomegalovirus-reactive cell-mediated immunity in hemodialysis patients. BMC Immunol. 2017;18:15.
Jarque M, Melilli E, Crespo E, Manonelles A, Montero N, Torras J, et al. CMV-specific cell-mediated immunity at 3-month prophylaxis withdrawal discriminates D+/R+ kidney transplants at risk of late-onset CMV infection regardless the type of induction therapy. Transplantation. 2018;102:e472–e80.
Rogers R, Saharia K, Chandorkar A, Weiss ZF, Vieira K, Koo S, et al. Clinical experience with a novel assay measuring cytomegalovirus (CMV)-specific CD4+ and CD8+ T-cell immunity by flow cytometry and intracellular cytokine staining to predict clinically significant CMV events. BMC Infect Dis. 2020;20:58.
Chemaly RF, El Haddad L, Winston DJ, Rowley SD, Mulane KM, Chandrasekar P, et al. Cytomegalovirus (CMV) cell-mediated immunity and CMV infection after allogeneic hematopoietic cell transplantation: the REACT study. Clin Infect Dis. 2020;71:2365–74.
Fernandez-Ruiz M, Rodriguez-Goncer I, Parra P, Ruiz-Merlo T, Corbella L, Lopez-Medrano F, et al. Monitoring of CMV-specific cell-mediated immunity with a commercial ELISA-based interferon-gamma release assay in kidney transplant recipients treated with antithymocyte globulin. Am J Transpl. 2020;20:2070–80.
Gliga S, Fiedler M, Dornieden T, Achterfeld A, Paul A, Horn PA, et al. Comparison of three cellular assays to predict the course of CMV infection in liver transplant recipients. Vaccines. 2021;9:88.
Callens R, Colman S, Delie A, Schauwvlieghe A, Lodewyck T, Selleslag D, et al. Immunologic monitoring after allogeneic stem cell transplantation: T-SPOT.CMV and QuantiFERON-CMV, are they the same? Transpl Cell Ther. 2023;29:392 e1–e7.
Zamora D, Duke ER, Xie H, Edmison BC, Akoto B, Kiener R, et al. Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation. Blood. 2021;138:34–43.
Gimenez E, Guerreiro M, Torres I, Aguilar C, Albert E, Hernandez-Boluda JC, et al. Features of cytomegalovirus DNAemia and virus-specific T-cell responses in allogeneic hematopoietic stem-cell transplant recipients during prophylaxis with letermovir. Transpl Infect Dis. 2023;25:e14021.
Lauruschkat CD, Muchsin I, Rein A, Erhard F, Grathwohl D, Dolken L, et al. CD4+ T cells are the major predictor of HCMV control in allogeneic stem cell transplant recipients on letermovir prophylaxis. Front Immunol. 2023;14:1148841.
Perchetti GA, Biernacki MA, Xie H, Castor J, Joncas-Schronce L, Ueda Oshima M, et al. Cytomegalovirus breakthrough and resistance during letermovir prophylaxis. Bone Marrow Transplant. 2023;58:430–6.
Zamora D, Xie H, Sadowska-Klasa A, Kampouri E, Biernacki MA, Ueda Oshima M, et al. CMV reactivation during pretransplantation evaluation: a novel risk factor for posttransplantation CMV reactivation. Blood Adv. 2024;8:4568–80.
Nesher L, Shah DP, Ariza-Heredia EJ, Azzi JM, Siddiqui HK, Ghantoji SS, et al. Utility of the enzyme-linked immunospot interferon-gamma-release assay to predict the risk of cytomegalovirus infection in hematopoietic cell transplant recipients. J Infect Dis. 2016;213:1701–7.
Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood. 1994;83:1971–9.
Hakki M, Riddell SR, Storek J, Carter RA, Stevens-Ayers T, Sudour P, et al. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. Blood. 2003;102:3060–7.
Marty FM, Bryar J, Browne SK, Schwarzberg T, Ho VT, Bassett IV, et al. Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood. 2007;110:490–500.
Sandmaier BM, Kornblit B, Storer BE, Olesen G, Maris MB, Langston AA, et al. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. Lancet Haematol. 2019;6:e409–e18.
Ueda Oshima M, Xie H, Zamora D, Flowers ME, Hill GR, Mielcarek MB, et al. Impact of GVHD prophylaxis on CMV reactivation and disease after HLA-matched peripheral blood stem cell transplantation. Blood Adv. 2023;7:1394–403.
Nashan B, Gaston R, Emery V, Saemann MD, Mueller NJ, Couzi L, et al. Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients. Transplantation. 2012;93:1075–85.
Gimenez E, Guerreiro M, Gozalbo-Rovira R, Aguilar C, Albert E, Pinana JL, et al. In vitro assessment of the combined effect of letermovir and sirolimus on cytomegalovirus replication. Rev Esp Quimioter. 2023;36:526–30.
Kean L, Siegel SJ, Schmalz JT, Bien SA, Scheffey D, Sanders C, et al. Large-scale post-transplant TCR deep sequencing reveals a major T cell diversity bottleneck with post-transplant cyclophosphamide with implications for both efficacy and toxicity: results of the BMT CTN 1801 study. Blood. 2023;142:475.
T-SPOT®.CMV [package insert] (Oxford-Immunotec, 2023).
